| editorial | Q871232 |
| scholarly article | Q13442814 |
| P50 | author | Guillermo Ruiz-Irastorza | Q37830875 |
| Munther A. Khamashta | Q73418907 | ||
| P2860 | cites work | A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome | Q28193536 |
| Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) | Q31107094 | ||
| Hydroxychloroquine in lupus pregnancy | Q33373145 | ||
| Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus | Q33974679 | ||
| Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial | Q33993957 | ||
| Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis | Q34648366 | ||
| Antimalarials may influence the risk of malignancy in systemic lupus erythematosus | Q35953395 | ||
| Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis | Q36747001 | ||
| The antiphospholipid syndrome and SLE: is there a clue in the link between complement and coagulation? | Q40951725 | ||
| Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events | Q41911950 | ||
| Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual | Q41912319 | ||
| Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred thirty‐three cases compared with a control group | Q41915008 | ||
| Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. | Q41919391 | ||
| Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice | Q41927420 | ||
| Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. | Q41930670 | ||
| Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus | Q41942520 | ||
| A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus | Q41942545 | ||
| Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids | Q41943371 | ||
| Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis | Q41944990 | ||
| Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. | Q43417859 | ||
| Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups | Q46660881 | ||
| Biochemical characterization of ADP-ribose polymer metabolism in SLE. | Q51031046 | ||
| Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. | Q54664586 | ||
| P433 | issue | 4 | |
| P921 | main subject | hydroxychloroquine | Q421094 |
| P1104 | number of pages | 3 | |
| P304 | page(s) | 271-273 | |
| P577 | publication date | 2008-04-01 | |
| P1433 | published in | Lupus | Q6704846 |
| P1476 | title | Hydroxychloroquine: the cornerstone of lupus therapy | |
| P478 | volume | 17 |
| Q41933390 | Autoimmune liver disease in patients with systemic lupus erythematosus: a retrospective analysis of 147 cases. |
| Q46364779 | Belimumab for systemic lupus erythematosus: a practice-based view |
| Q37782472 | Cutaneous lupus erythematosus: Update of therapeutic options |
| Q41922310 | Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study |
| Q38756983 | Hydroxychloroquine affects bone resorption both in vitro and in vivo. |
| Q49366219 | Hydroxychloroquine decreases human MSC-derived osteoblast differentiation and mineralization in vitro. |
| Q55507790 | Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. |
| Q41929433 | Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. |
| Q34162739 | Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus |
| Q47396929 | Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome? |
| Q34937950 | Mucocutaneous manifestations in juvenile-onset systemic lupus erythematosus: a review of literature |
| Q38816742 | New Perspectives in Rheumatology: Avoiding Antimalarial Toxicity |
| Q38851096 | Preventing the development of SLE: identifying risk factors and proposing pathways for clinical care |
| Q52316454 | Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. |
| Q35877606 | Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis |
| Q52836583 | S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). |
| Q50231899 | Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa. |
| Q88477714 | Sharp decline in hydroxychloroquine dosing-analysis of 17,797 initiators from 2007 to 2016 |
| Q51834159 | Systemic lupus erythematosus. |
| Q34498515 | Systemic lupus erythematosus: review of synthetic drugs |
| Q35692998 | The Diagnosis and Treatment of Systemic Lupus Erythematosus |
| Q38561490 | Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases |
| Q34548422 | Treatment of Cutaneous Lupus Erythematosus: Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence-based Medicine Criteria. |
| Q50092295 | Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014). |
| Q89894663 | [Tapering and termination of immunosuppressive therapy : Systemic lupus erythematosus] |
Search more.